Electro-Optical announces positive study results for melanoma device
Electro-Optical Sciences Inc. of Irvington announced positive results from a study of MelaFind, an instrument the company is developing to help doctors detect melanoma, a deadly form of skin cancer.
The study, involving 1,383 patients at seven treatment centers nationally, found that MelaFind had a 98 percent success rate in detecting melanoma. The company said that it expects to soon submit an application seeking approval of the device with the U.S. Food and Drug Administration.
“MelaFind appears to be an excellent tool to help detect melanoma at the earliest, most treatable stage,” Gary D. Monheit, associate clinical professor of dermatology at the University of Alabama in Birmingham and the lead investigator for the MelaFind trial, said in a written statement.